Analytical Data
-
基因名
RPE65
- Application
-
别名
RPE65；Retinoid isomerohydrolase
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q16518
-
表达区间
2-533aa
-
氨基酸序列
SIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS
-
分子量
64.7 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RPE65 is a key protein involved in the visual cycle, specifically in the isomerization of retinol, which is crucial for the regeneration of visual pigments in the retinal pigment epithelium (RPE). Mutations in the RPE65 gene are associated with inherited retinal dystrophies, such as Leber congenital amaurosis and retinitis pigmentosa, leading to severe vision loss or blindness. Research on RPE65 has gained momentum due to the potential for gene therapy as a treatment for these conditions. In particular, the development of novel therapies, such as the FDA-approved gene therapy Luxturna, which delivers a functional copy of the RPE65 gene via an adeno-associated virus (AAV) vector, has demonstrated promising results in restoring vision in affected individuals. Understanding the structure and function of the RPE65 protein, along with its role in visual processes, is critical for advancing these therapeutic strategies. Furthermore, studies on RPE65 also explore its interactions with other proteins in the visual cycle and the biochemical pathways it influences, aiming to enhance the efficacy of existing treatments and develop new interventions for retinal diseases. As such, RPE65 remains a focal point in retinal research, driving innovations in gene therapy and shedding light on the molecular basis of retinal health and disease.
